EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

MIS ‐C Overlap, Not Prior COVID ‐19 Itself, Drives Treatment Escalation in Kawasaki Disease: A Nationwide Cohort Study

Min Ji Kim iD, Jong Seung Kim iD, Jee Young Hong iD, Jihye You iD

Pediatrics International · 2026-01 · 68 (1)

DOI: 10.1111/ped.70476 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Pediatrics International, online erschienen am 13.07.2026. Verfasst von Min Ji Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Informatics, Jeonbuk National University Medical School, Jeonju, Korea. Hauptthemen laut MEDLINE: Mucocutaneous Lymph Node Syndrome, Immunoglobulins, Intravenous, COVID-19, Systemic Inflammatory Response Syndrome. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Fund of the Biomedical Research Institute, Jeonbuk National University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Whether prior coronavirus disease 2019 (COVID‐19) independently influences treatment response in children with Kawasaki disease (KD) is unclear, as prior reports may have been confounded by overlap with multisystem inflammatory syndrome in children (MIS‐C). We investigated this in a nationwide cohort, accounting for these factors.

Methods

We conducted a retrospective cohort study using the Korean National Health Insurance Service database. Children diagnosed with KD on or after January 1, 2020 who received IVIG within 7 days were included. Prior COVID‐19 was defined as documented infection within 3 months before KD diagnosis. The primary outcome was second‐line treatment within 7 days after initial IVIG (composite of second IVIG or additional steroid). 1:1 propensity score matching was performed using age, sex, MIS‐C status, and steroid use with initial IVIG.

Results

Among 6572 eligible children, 512 had prior COVID‐19; 431 patients were matched per group. Second‐line treatment occurred in 32/431 (7.4%) versus 23/431 (5.3%) ( p = 0.265). Prior COVID‐19 was not independently associated with second‐line treatment (adjusted HR 1.42; 95% CI 0.83–2.43). In subgroup analysis, elevated risk was confined to children with concurrent MIS‐C (HR 3.01; 95% CI 1.34–6.74); prior COVID‐19 without MIS‐C showed no increase (HR 1.18; 95% CI 0.66–2.11). Sensitivity analyses excluding MIS‐C and restricted to 2022 onward were consistent.

Conclusions

Prior COVID‐19 alone was not independently associated with second‐line treatment once MIS‐C overlap and concurrent steroid use were accounted for. The elevated treatment escalation rate appeared driven primarily by MIS‐C, highlighting the importance of distinguishing MIS‐C from classic KD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mucocutaneous Lymph Node SyndromeImmunoglobulins, IntravenousCOVID-19Systemic Inflammatory Response SyndromeHumansMaleFemaleRetrospective StudiesChild, PreschoolRepublic of KoreaInfantChildImmunologic FactorsTreatment Outcome

Stichwörter der Autor:innen

COVID‐19Kawasaki diseaseSARS‐CoV‐2intravenous immunoglobulinsmultisystem inflammatory syndrome in children

Substanzen

Immunoglobulins, IntravenousImmunologic Factors

Autor:innen und Institutionen

  • Department of Medical Informatics, Jeonbuk National University Medical School, Jeonju, Korea.
  • Department of Otorhinolaryngology-Head and Neck Surgery, Jeonbuk National University Hospital, Jeonju, Korea.
  • Department of Preventive Medicine, College of Medicine, Jeonbuk National University, Jeonju, Korea.
  • Research Institute of Clinical Medicine of Jeonbuk National University, Jeonju, Korea.
  • Department of Pediatrics, Jeonbuk National University Children's Hospital, Jeonju, Korea.

ORCID-Profile: Min Ji Kim, Jong Seung Kim, Jee Young Hong, Jihye You

Förderung

  • the Fund of the Biomedical Research Institute, Jeonbuk National University Hospital

Zitieren

APA

Kim, M. J., Kim, J. S., Hong, J. Y., & You, J. (2026). MIS ‐C Overlap, Not Prior COVID ‐19 Itself, Drives Treatment Escalation in Kawasaki Disease: A Nationwide Cohort Study. Pediatrics International, 68(1). https://doi.org/10.1111/ped.70476

Vancouver

Kim MJ, Kim JS, Hong JY, You J. MIS ‐C Overlap, Not Prior COVID ‐19 Itself, Drives Treatment Escalation in Kawasaki Disease: A Nationwide Cohort Study. Pediatrics International. 2026;68(1). doi:10.1111/ped.70476

BibTeX
@article{Kim2026,
  author = {Kim, Min Ji and Kim, Jong Seung and Hong, Jee Young and You, Jihye},
  title = {MIS ‐C Overlap, Not Prior COVID ‐19 Itself, Drives Treatment Escalation in Kawasaki Disease: A Nationwide Cohort Study},
  journal = {Pediatrics International},
  year = {2026},
  volume = {68},
  number = {1},
  doi = {10.1111/ped.70476}
}
Kostenlos starten →